<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973151</url>
  </required_header>
  <id_info>
    <org_study_id>HL-085-101</org_study_id>
    <nct_id>NCT03973151</nct_id>
  </id_info>
  <brief_title>Study of HL-085 in NRAS Mutant Advanced Melanoma</brief_title>
  <official_title>A Phase I/II, Single Arm, Dose Escalation and Cohort Expansion Study to Evaluate Safety, Preliminary Efficacy of HL-085 in Patients With NRAS Mutant Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Kechow Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Kechow Pharma, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II, open-label, dose escalation study to evaluate tolerability, safety,
      pharmacokinetics and efficacy in patients with NRAS mutant advanced melanoma .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Duration of the study, estimated to be approximately 24 months.</time_frame>
    <description>Number of Treatment-Related Adverse Events as Assessed by CTCAE v4.03 during the study period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>DLTs within the first cycle of therapy (up to 35 days)</time_frame>
    <description>The dose level immediately below the dose level at which ≥ 2 patients from a cohort of 3 to 6 patients experience a dose-limiting toxicity (DLT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) as measure of efficacy</measure>
    <time_frame>Duration of the study, estimated to be approximately 24 months.</time_frame>
    <description>Efficacy estimated as the Objective Response Rate (ORR) , which is the sum of Partial Response (PR) and Complete Response (CR) as determined by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Duration of the study, estimated to be approximately 24 months</time_frame>
    <description>AUC of HL-085 following single and repeated dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Duration of the study, estimated to be approximately 24 months</time_frame>
    <description>Cmax of HL-085 following single and repeated dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed plasma drug concentration (Tmax)</measure>
    <time_frame>Duration of the study, estimated to be approximately 24 months.</time_frame>
    <description>Tmax of HL-085 following single and repeated dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2)</measure>
    <time_frame>Duration of the study, estimated to be approximately 24 months.</time_frame>
    <description>T1/2 of HL-085 following single and repeated dosing</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>HL-085</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL-085 will be administered as BID with specified dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL-085</intervention_name>
    <description>HL-085 is one MEK inhibitor.</description>
    <arm_group_label>HL-085</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed unresectable Stage III or Stage IV melanoma
             according to AJCC (Version 7, 2010).

          2. Subjects must have NRAS mutation in melanoma.

          3. Chemotherapy, immunotherapy or radiotherapy ≥ 4 weeks prior to starting the study
             treatment. Surgery (except for tumor biopsy) or severe trauma ≤ 14 days prior to
             starting the study treatment.

          4. ECOG performance status of 0-1.

          5. Life expectancy ≥ 3 months.

          6. Ability to take the medicine orally.

          7. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Prior therapy with a MEK-inhibitor

          2. Patients with known hypersensitivity to study drug ingredients or their analogues.

          3. Active central nervous system (CNS) lesion.

          4. ECG QTcB≥480msec in screening, or history of congenital long QT syndrome.

          5. Subjects with bleeding symptoms at Grade 3 (NCI-CTCAE v4.03) within 4 weeks prior to
             starting study treatment.

          6. Uncontrolled concomitant diseases or infectious diseases.

          7. Retinal diseases (Retinal Vein Occlusion (RVO) or Retinal pigment epithelial
             detachment (RPED) , et al.).

          8. History of HIV,HCV,HBV infection.

          9. Interstitial lung disease or interstitial pneumonitis, including clinically
             significant radiation pneumonitis will be excluded.

         10. Serum HCG test is positive.

         11. Other conditions that influence the results and increase the risk of study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Liu, M.D,Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Kechow Pharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Liu, MD,Ph.D</last_name>
    <phone>86 21 51323990</phone>
    <email>liuy@kechowpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Guo, M.D.</last_name>
      <phone>+86-10-88121122</phone>
      <email>guoj307@126.com</email>
    </contact>
    <investigator>
      <last_name>Jun Guo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>June 1, 2019</last_update_submitted>
  <last_update_submitted_qc>June 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>NRAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

